What is New in Non-Steroidal Topical Options for Atopic Dermatitis and Psoriasis: Clinical Insights for Dermatology PAs and NPs : FCPANP23 Seminar-in-Depth
Phase 3 ADORING2 study with tapinarof in children with atopic dermatitis ages 2 and above show approximately a 50% improvement in? Start the activity to find out the answer!
a. V-IGA-AD but not EASI75 and PP-NRS
b. V-IGA-AD and EASI75 but not PP-NRS
c. V-IGA-AD and EASI75 and PP-NRS
d. EASI75 and PP-NRS but not V-IGA-AD
This activity is supported by an educational grant from Arcutis, Dermavant, and Incyte.
At the completion of this activity, participants should be better able to:
Identify challenges associated with the use of topical corticosteroids in patients with AD and psoriasis
Review nonsteroid topical agents for the treatment of AD and psoriasis
Discuss clinical considerations for PAs and NPs who prescribe topical therapies to patients with AD and psoriasis
James Del Rosso, DO
Adjunct Clinical Professor, Dermatology
Touro University Nevada
Linda Stein Gold, MD
Director Clinical Research
Henry Ford Health System
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of University of Nevada and CMEsquared. The University of Nevada is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The University of Nevada designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures & Disclaimers
Disclosures are as follows:
Grant/Research Support: Aclaris, Amgen, Anaptys Bio, Arcutis, Athenex, Bausch (Ortho), Biorasi, Botanix, Brickell, Cara Therapeutics, Cassiopea, Dermavant, EPI Health, Galderma, Genentech, Incyte, Janssen, LEO, Lilly, Novan, Pfizer, Ralexar, Sanofi Genzyme Regeneron, Sol-Gel, SUN, Vyne
Consultant: Abbvie, Aclaris, Almirall, Amgen, Arcuits, Bausch (Ortho), Biofrontera, Biopharmx, Blue Creek, BMS, Cassiopea, Dermata, Dermavant, Encore, EPI Health, Evoummune, Ferndale, Galderma, Incyte, Jem Health, LEO, La Roche Posay, Lilly, MC2, Novan, Pfizer, Sanofi Genzyme Regeneron, Sente, Sol-Gel, Sonoma, SUN, UCB, Verrica, Vyne
Speakers’ Bureau or Honoraria: Abbvie, Aclaris, Almiral, Amgen, Bausch (Ortho), Biofrontera, Encore, EPI Health Ferndale, Galderma, Genentech, Jem Health, LEO, Lilly, Pfizer, Sanofi Genzyme Regeneron, SUN, UCB, Verrica, Vyne
Grant/Research Support: Arcutis, BMS, Incyte, Dermavant, Galderma, Lilly, AbbVie
Consultant: Arcutis, BMS, Incyte, Dermavant, Galderma, Lilly, AbbVie
Speakers’ Bureau or Honoraria: Leo, AbbVie, Almirall, Galderma, Pfizer, Sanofi, Regeneron
The University of Nevada discloses that all relevant conflicts have been satisfactorily mitigated.